揭开潜力:癌症中的mRNA疗法
Karol Gawalski1,2, Weronika Przybyszewska2,3, Jaromir Hunia1,2
1Laboratory of Experimental Medicine, Medical University of Warsaw, Warsaw, Poland.
Frontiers in oncology
|August 29, 2025
概括
通过刺激对瘤抗原的免疫反应,信使RNA (mRNA) 技术为癌症免疫治疗提供了一种新的方法. 针对新抗原的个性化mRNA疫苗有望治疗各种癌症,并可能与其他疗法结合使用.
科学领域:
- 癌症学
- 免疫学
- 生物技术
背景情况:
- 自发现以来,信使RNA (mRNA) 技术已经显著发展,现在作为癌症免疫治疗的关键平台.
- 与传统疫苗不同,mRNA在瘤学中的作用是增强免疫系统对瘤抗原的反应.
- 最近的突破和诺贝尔奖获奖的研究突出了mRNA在癌症治疗中的潜力.
研究的目的:
- 为癌症免疫治疗提供mRNA技术的全面概述.
- 讨论基于mRNA的癌症疫苗的历史发展,当前应用和未来前景.
- 探索开发有效的mRNA癌症疗法的挑战和进展.
主要方法:
- 关于mRNA技术在瘤学中的历史数据,科学文献和临床试验结果的审查.
- 分析不同的mRNA治疗策略,包括抗原向和输送系统.
- 对生物信息学,人工智能和新抗原识别的机器学习技术进步的研究.
主要成果:
- mRNA技术可针对多种瘤抗原,包括瘤相关抗原和瘤特异性新抗原.
- 针对黑色素瘤和肺癌等恶性瘤的临床试验中正在研究各种输送系统 (例如脂质纳米颗粒) 和输送途径.
- 早期试验显示出有前途的安全性和有效性,其中一些进展到第三阶段.
结论:
- 虽然普遍的mRNA癌症疫苗因瘤异质性而面临挑战,但针对新抗原的个性化mRNA疫苗是一个可行的和有前途的解决方案.
- 生物信息学和人工智能的进步提高了针对个性化疫苗的免疫新表位的识别.
- 将mRNA疗法与免疫检查点抑制剂等疗法相结合可能为癌症治疗提供新的途径.
相关概念视频
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:56Riboswitches
8.5K
Riboswitches are non-coding mRNA domains that regulate the transcription and translation of downstream genes without the help of proteins. Riboswitches bind directly to a metabolite and can form unique stem-loop or hairpin structures in response to the amount of the metabolite present. They have two distinct regions – a metabolite-binding aptamer and an expression platform.
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
8.5K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:22Regulated mRNA Transport
2.9K
2.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K